speedy/RINGO cell cycle regulator family member E6Genealiases: []
Q-omics provides the consensus-scored SPDYE6 profile across patient tissues and cancer cell-line models. SPDYE6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, SPDYE6 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, SPDYE6 RNA expression shows 16,798 significant gene co-expression associations, with the highest sampling consensus in SCLC. Together, these results highlight LGG, BLCA, and SCLC as cancer lineages where SPDYE6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE6 survival associations across molecular data types. SPDYE6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE6 RNA expression–survival associations across cancer types. High SPDYE6 expression shows unfavorable associations in LGG, KICH, ACC and COAD, but favorable associations in UCS and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for SPDYE6 RNA expression.
This table summarizes SPDYE6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE6 shows higher tumor expression in BLCA, LIHC, UCEC, HNSC, STAD and BRCA. The BLCA box plot shows higher SPDYE6 RNA expression in tumor versus normal tissue (log2 FC = +0.390, t-test p = .002).
This table shows molecular features associated with SPDYE6 in patient tissues and cancer cell lines. In patient samples, SPDYE6 shows the broadest associations at the RNA and protein expression levels, with SCLC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPDYE6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
